News

IMI launches seven projects
Enlarge image

FundingEUFranceUK

IMI launches seven projects

11.06.2012 - The Innovative Medicines Initiative (IMI) has announced details on seven projects funded with a total budget of €215m.

The projects funded within the next five years include two coordinated by GlaxoSmithKline plc: model-based preclinical development of anti-tuberculosis (TB) drug combinations (PreDiCT-TB), which aim to make tuberculosis treatments more patient-friendly; and development of tools to predict immune response to biopharmaceuticals (ABIRISK). Sanofi is coordinating the DIRECT project to research patient stratification for personalised Type II diabetes treatments. Novartis AG and The University of Surrey (UK) are working on a project to develop biomarkers to test the safety of vaccines (BIOVACSAFE). A project coordinated by AstraZeneca plc is to develop tests for drug-induced liver injury (MIP-DILI); and one consortium coordinated by Roche seeks to develop research tools and diagnostics for autism spectrum disorder (EU-AIMS). 

IMI also announced the launch of a Education and Training project called EUPATI, which shall create a European Patients’ Academy on Therapeutic Innovation. Its aim is to educate patients and the public about medicines development and empower patients to engage more effectively in the drug development process. The new projects mean that IMI is now supporting a total of 30 projects with a combined total cost of over €650m. IMI is a public-private partnership in health research and development. The European Union contributes €1 bn to the IMI research programme, which is matched by contributions worth at least another €1bn from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

http://www.european-biotechnology-news.com/news/news/2012-02/imi-launches-seven-projects.html

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR30.9%
  • CO.DON3.13 EUR26.2%
  • FORMYCON8.03 EUR17.7%

FLOP

  • CYTOS0.19 CHF-24.0%
  • ADDEX3.13 CHF-21.4%
  • EVOTEC3.06 EUR-18.2%

TOP

  • SANTHERA88.65 CHF2088.9%
  • PAION3.18 EUR238.3%
  • CO.DON3.13 EUR229.5%

FLOP

  • CYTOS0.19 CHF-95.1%
  • 4SC1.06 EUR-45.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 29.09.2014